HY-165622 Search Results


sn38  (MedChemExpress)
95
MedChemExpress sn38
a Bar plot representation of the progression-free survival (PFS) in months per patient. b NDR results upon treatment with gemcitabine-paclitaxel highlighting the 3 distinct responses. Error bars indicate the standard deviation. c Representative brightfield/fluorescence (Cytotox Green) images of PDAC052, PDAC060 and PDAC082 indicating the presence of persistent PDAC organoid clones (black circle). One representative image was selected for visualization out of the two technical replicates. Scale bar=100 µm d Single organoid dose response based on cell death (green area/brightfield area) labeled as fraction affected and area (brightfield) of PDAC052, PDAC060 and PDAC082 treated with gemcitabine-paclitaxel (400 nM:80 nM). Dark grey region (Fraction affected <0.15) indicates resistant, middle grey region sensitive (Fraction affected 0.15-0.34) and light grey highly sensitive (Fraction affected >0.34) PDAC organoid clones. Bubble size correlates with the organoid area. e Relative fraction of resistant, sensitive and highly sensitive PDAC organoids for each patient treated with gemcitabine-paclitaxel (400 nM:80 nM). f Dynamic quantification of single-organoid responses treated with gemcitabine-paclitaxel (400 nM:80 nM) or FOLFIRINOX (20 µM 5-FU:0.0625 µM <t>SN38:2.5</t> µM Oxaliplatin). The single organoid data was combined from 2 technical replicates.
Sn38, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sn38/product/MedChemExpress
Average 95 stars, based on 1 article reviews
sn38 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
irinotecan  (MedChemExpress)
99
MedChemExpress irinotecan
a Bar plot representation of the progression-free survival (PFS) in months per patient. b NDR results upon treatment with gemcitabine-paclitaxel highlighting the 3 distinct responses. Error bars indicate the standard deviation. c Representative brightfield/fluorescence (Cytotox Green) images of PDAC052, PDAC060 and PDAC082 indicating the presence of persistent PDAC organoid clones (black circle). One representative image was selected for visualization out of the two technical replicates. Scale bar=100 µm d Single organoid dose response based on cell death (green area/brightfield area) labeled as fraction affected and area (brightfield) of PDAC052, PDAC060 and PDAC082 treated with gemcitabine-paclitaxel (400 nM:80 nM). Dark grey region (Fraction affected <0.15) indicates resistant, middle grey region sensitive (Fraction affected 0.15-0.34) and light grey highly sensitive (Fraction affected >0.34) PDAC organoid clones. Bubble size correlates with the organoid area. e Relative fraction of resistant, sensitive and highly sensitive PDAC organoids for each patient treated with gemcitabine-paclitaxel (400 nM:80 nM). f Dynamic quantification of single-organoid responses treated with gemcitabine-paclitaxel (400 nM:80 nM) or FOLFIRINOX (20 µM 5-FU:0.0625 µM <t>SN38:2.5</t> µM Oxaliplatin). The single organoid data was combined from 2 technical replicates.
Irinotecan, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/irinotecan/product/MedChemExpress
Average 99 stars, based on 1 article reviews
irinotecan - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

Image Search Results


a Bar plot representation of the progression-free survival (PFS) in months per patient. b NDR results upon treatment with gemcitabine-paclitaxel highlighting the 3 distinct responses. Error bars indicate the standard deviation. c Representative brightfield/fluorescence (Cytotox Green) images of PDAC052, PDAC060 and PDAC082 indicating the presence of persistent PDAC organoid clones (black circle). One representative image was selected for visualization out of the two technical replicates. Scale bar=100 µm d Single organoid dose response based on cell death (green area/brightfield area) labeled as fraction affected and area (brightfield) of PDAC052, PDAC060 and PDAC082 treated with gemcitabine-paclitaxel (400 nM:80 nM). Dark grey region (Fraction affected <0.15) indicates resistant, middle grey region sensitive (Fraction affected 0.15-0.34) and light grey highly sensitive (Fraction affected >0.34) PDAC organoid clones. Bubble size correlates with the organoid area. e Relative fraction of resistant, sensitive and highly sensitive PDAC organoids for each patient treated with gemcitabine-paclitaxel (400 nM:80 nM). f Dynamic quantification of single-organoid responses treated with gemcitabine-paclitaxel (400 nM:80 nM) or FOLFIRINOX (20 µM 5-FU:0.0625 µM SN38:2.5 µM Oxaliplatin). The single organoid data was combined from 2 technical replicates.

Journal: NPJ Precision Oncology

Article Title: Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer

doi: 10.1038/s41698-023-00480-y

Figure Lengend Snippet: a Bar plot representation of the progression-free survival (PFS) in months per patient. b NDR results upon treatment with gemcitabine-paclitaxel highlighting the 3 distinct responses. Error bars indicate the standard deviation. c Representative brightfield/fluorescence (Cytotox Green) images of PDAC052, PDAC060 and PDAC082 indicating the presence of persistent PDAC organoid clones (black circle). One representative image was selected for visualization out of the two technical replicates. Scale bar=100 µm d Single organoid dose response based on cell death (green area/brightfield area) labeled as fraction affected and area (brightfield) of PDAC052, PDAC060 and PDAC082 treated with gemcitabine-paclitaxel (400 nM:80 nM). Dark grey region (Fraction affected <0.15) indicates resistant, middle grey region sensitive (Fraction affected 0.15-0.34) and light grey highly sensitive (Fraction affected >0.34) PDAC organoid clones. Bubble size correlates with the organoid area. e Relative fraction of resistant, sensitive and highly sensitive PDAC organoids for each patient treated with gemcitabine-paclitaxel (400 nM:80 nM). f Dynamic quantification of single-organoid responses treated with gemcitabine-paclitaxel (400 nM:80 nM) or FOLFIRINOX (20 µM 5-FU:0.0625 µM SN38:2.5 µM Oxaliplatin). The single organoid data was combined from 2 technical replicates.

Article Snippet: Cytotox Green (60 nM / well, Sartorius), Staurosporine (2 µM), 5-Fluorouracil (5-FU), SN38 (active metabolite Irinotecan), gemcitabine and paclitaxel (MedChemExpress) were dissolved in DMSO.

Techniques: Standard Deviation, Fluorescence, Clone Assay, Labeling

a – c Spearman rank correlation of the % sensitive, % resistant and ratio % sensitive/resistant PDAC clones (gemcitabine-paclitaxel; 400 nM: 80 nM) with the PFS. d . Correlation of % ratio sensitive/resistant with the initial clinical response to gemcitabine-paclitaxel. Responses were based on available radiological CT protocols. Good= tumor regression and/or PFS > 10 months, Mixed= minor tumor regression, Bad= no tumor regression and/or fast disease progression. e NDR signatures indicating the NDR value (left y-axis) and % cell death (right y-axis) upon treatment with gemcitabine-paclitaxel (400 nM:80 nM) or FOLFIRINOX (4 µM 5-FU:0.0125 µM SN38:0.5 µM Oxaliplatin). f Representative CT-scans before and after treatment with gemcitabine/nab-paclitaxel or FOLFIRINOX (8 cycles). Red contours indicate the tumor margins. g Overview of the clinical characteristics of patient PDAC044, PDAC052, PDAC060, PDAC068 and PDAC087. h Comparison of the implemented readouts, suggesting a potential clinical application of combining the NDR readout with the developed single-organoid analysis.

Journal: NPJ Precision Oncology

Article Title: Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer

doi: 10.1038/s41698-023-00480-y

Figure Lengend Snippet: a – c Spearman rank correlation of the % sensitive, % resistant and ratio % sensitive/resistant PDAC clones (gemcitabine-paclitaxel; 400 nM: 80 nM) with the PFS. d . Correlation of % ratio sensitive/resistant with the initial clinical response to gemcitabine-paclitaxel. Responses were based on available radiological CT protocols. Good= tumor regression and/or PFS > 10 months, Mixed= minor tumor regression, Bad= no tumor regression and/or fast disease progression. e NDR signatures indicating the NDR value (left y-axis) and % cell death (right y-axis) upon treatment with gemcitabine-paclitaxel (400 nM:80 nM) or FOLFIRINOX (4 µM 5-FU:0.0125 µM SN38:0.5 µM Oxaliplatin). f Representative CT-scans before and after treatment with gemcitabine/nab-paclitaxel or FOLFIRINOX (8 cycles). Red contours indicate the tumor margins. g Overview of the clinical characteristics of patient PDAC044, PDAC052, PDAC060, PDAC068 and PDAC087. h Comparison of the implemented readouts, suggesting a potential clinical application of combining the NDR readout with the developed single-organoid analysis.

Article Snippet: Cytotox Green (60 nM / well, Sartorius), Staurosporine (2 µM), 5-Fluorouracil (5-FU), SN38 (active metabolite Irinotecan), gemcitabine and paclitaxel (MedChemExpress) were dissolved in DMSO.

Techniques: Clone Assay, Comparison